One of the major problems women diagnosed with ovarian cancer face is lack of treatments. There are only a few choices for these women, and many options are not as effective when caught later in the progression of the disease. That’s why, when researchers uncover a potential new treatment, it’s important to learn more about it. According to new research:
“researchers are beginning clinical trials into new cancer drug, ALM201, which “targets tumours by an entirely different pathway to other treatments”.
Rather than attacking tumours directly, it prevents the growth of new blood vessels in tumours by starving them of oxygen and nutrients.
If the clinical trials are successful, ALM201 could also be used to treat other forms of cancer.
It has been created by Co Armagh-based drugs firm Almac Discovery in conjunction with experts from Queen’s University, Belfast.
They have been working on ALM201 for six years, with the process now reaching clinical trial stage.
The phase 1 trials were announced to coincide with the start of Ovarian Cancer Month.
Stephen Barr, president of Almac Discovery, said: “This is a significant step in tailoring patient therapy and we are excited to be involved in advancing human health in this way.””
Learn more by reading the original article over at the Mirror: http://www.mirror.co.uk/lifestyle/health/ovarian-cancer-drug-tested-patients-5260612
0 comments:
Post a Comment